Disease Focus Areas

In 2024, Sabin partnered with the Kenya Medical Research Institute (KEMRI) to optimize the use of the oral cholera vaccine.

We provide tools to immunization professionals in low- and middle-income countries to advance vaccine equity. We help frontline health workers counter misinformation, collect data about interventions and share their lessons.

A Sabin-hosted public-private movement to prevent Human Papilloma Virus (HPV) infection and eliminate cervical cancer as a public health concern.

We’re convening experts across the science and technology landscape, vaccine development and regulatory science, public-private partnerships and pandemic preparedness to bring new thinking to solve one of the oldest and deadliest diseases – influenza.

We’re developing a vaccine for Marburg, a virus similar to Ebola, and one of the world’s deadliest infectious diseases.

In 2022, there were an estimated 249 million malaria cases worldwide, with the majority occurring in the tropical regions, making this disease a priority area for Sabin.

Since 2019, we’ve been developing a vaccine for Sudan ebolavirus to prevent this deadly virus.

We work to ensure that countries where typhoid is common have the data they need to make strategic decisions about introducing typhoid vaccines. We also partner with scientists and health workers to advance a holistic approach to preventing disease.